Actelion (VTX:ATLN) shareholders today reportedly approved spinning off the company’s early clinical assets and drug discovery branch into a new company. The move keeps Johnson & Johnson (NYSE:JNJ) $30 billion takeover on track to close in the 2nd quarter.
The newly formed biopharmaceutical company will be called Idorsia Ltd and led by Actelion CEO Jean-Paul Clozel. Shares in Idorsia are expected to list on the SIX Swiss Exchange on the day that Johnson & Johnson’s tender offer closes.
Get the full story at our sister site, Drug Delivery Business News.
The post Actelion shareholders OK R&D spinout appeared first on MassDevice.
from MassDevice http://ift.tt/2oIuyYG
Cap comentari:
Publica un comentari a l'entrada